公开(公告)号：US20240058441A1

公开(公告)日：2024-02-22

申请号：US17766450

申请日：2021-05-18

申请人： SUN YAT-SEN UNIVERSITY ,  SUN YAT-SEN UNIVERSITY CANCER CENTER (SYSUCC)

发明人： Musheng Zeng ,  Jie Yang ,  Guokai Feng ,  Qiaoli Wang

IPC分类号： A61K39/395 ,  A61K38/46 ,  C07K16/40 ,  A61K31/5377 ,  A61P35/00 ,  C12N9/64

CPC分类号： A61K39/3955 ,  A61K38/46 ,  C07K16/40 ,  A61K31/5377 ,  A61P35/00 ,  C12N9/6424 ,  C12Y304/21 ,  C07K2319/33 ,  C07K2317/569

摘要： Disclosed are a fusion protein, and a preparation method and use thereof, which belong to the field of biomedicine technologies. The fusion protein comprises a polypeptide specifically bound to a KRas protein, a specific tumor-cell-penetrating peptide and a lysosome recognition peptide. The fusion protein with tumor targeting, penetrability and specific protein degradation is designed and constructed direct to an undruggable protein for the first time, thus providing a new idea for development of an anti-cancer targeted drug. Different from the prior art in which one molecule can only target one target protein, the fusion protein can simultaneously induce degradation of wild-type and mutant-type KRas proteins. Meanwhile, the fusion protein can improve the sensitivity of the KRas mutant-type tumor to the tumor-targeted drug by inducing degradation of KRas, thus expanding an application range of existing anti-cancer targeted drugs and having important significance in tumor clinic treatment.